2019 BioPacific Conference (21th Annual Conference of CABS) Agenda
Theme: Pursuing Science for Cure
San Mateo Marriott, 1770 South Amphlett Blvd, San Mateo, CA 94402
| 8:00 AM – 8:40 AM | REGISTRATION |
| 8:40 AM – 8:45 AM | Welcome Remarks Yang Tian, PhD, President-elect of CABS and 2019 BioPacific Conference Organizing Committee Chair |
| 8:45 AM – 9:00 AM | State of the Society Yan Wang, PhD, President of CABS |
| 9:00 AM – 9:30 AM | Keynote: Biomarkers and Translational Research in Cancer Therapy Ron Mazumder, PhD, Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech |
| 9:30 AM – 10:00 AM | Talk title: New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation Jason Liu, PhD, MBA, CEO, WuXi Diagnostics |
| 10:00 AM-10:50 AM | CABS K. Fong Award in Life Sciences Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures Awardee: John Oyler, Founder, CEO and Chairman of BeiGene |
| 10:50 AM-11:00 AM – Coffee Break | |
| 11:00 AM – 11:30 AM | Designing Therapies to Cure HIV Romas Geleziunas, PhD, Executive Director, Gilead Sciences |
| 11:30 AM – 11:40 AM | Fireside Chat: Moderator: Alex J. Zhang, PhD, CEO, Hanhai Silicon Valley Jun Xiang, PhD, General Manager, ChemPartner Biologics |
| 11:40 AM – 12:05 PM | Panel Discussion:Key Developments: CFIUS, Export Control Reform, and Recent Decisions Affecting Life Sciences Investment and Licensing Joseph Benkert, Senior Advisor, Morrison Foerster |
| 12:05 AM – 12:30 PM | Panel Discussion: IP, legal and investment in Life Sciences Moderator, Huijun Zhou, FACMG, Founder and CEO, iDNA Panelists, Joseph Benkert, Senior Advisor, Morrison Foerster Panelists,Greg Scott, Founder and Chairman, ChinaBio Panelists,Michael Su, MS, JD, Attorney, Intellectual Property Law, Finnegan Panelists,Vivien Wang, MS, Partner, Deloitte |
| 12:30 PM – 1:30 PM – Lunch Break | |
| 12:45 PM – 1:15 PM | Lunch Workshop: Humanized Mouse Model Accelerates Biomedicine Research & Drug Development Ming Yin, PhD, VP, Beijing VitalStar Biotechnology |
| 1:30 PM – 2:00 PM | New Approaches To Neurodegenerative Disease Drug Discovery and Development Zach Sweeney, PhD, Head of Therapeutic Discovery, Denali Therapeutics |
| 2:00 PM – 2:30 PM | Panel Discussion: Innovative and Collaborative Contract Services to Accelerate Drug Development Moderator: Jiangwen Majeti, PhD, MBA, Genentech Panelists: Tao He, PhD, Co-Founder and SVP, Joinn Biologics Connie Sun, PhD, SVP, Pharmaron Mike Chen, CEO, AcroBio |
| 2:30 PM – 3:00 PM | Applying Precision Medicine One Patient at a Time Shivaani Kummar, MD, Professor of Medicine and Director of Phase I Clinical Research Program (Oncology), Stanford University |
| 3:00 PM – 3:10PM – Coffee Break | |
| 3:10 PM – 3:50 PM | Panel Discussion: innovative therapy in oncology, what is next? Moderator: Cheni Kwok, PhD, CLP, Managing Partner and Founder, Linear Dreams Panelists, Scott Liu, PhD, CEO, Henlius Panelists, Jean Cui, PhD, CSO, Turning Point Therapeutics Panelists, Mark Nevins, MS, VP of Business Development, Apexigen Panelists, Peiwen Yu, PhD, VP of Discovery Biology, Exelixis Panelists, Tara Arvedson, PhD, Director of Research, Amgen Panelists, Charlene Liao, PhD, Co-founder, President and CEO, Immune-Onc Therapeutics Panelists, Yanyan Zheng, PhD, Principle Scientist, Merck |
| 3:50 PM – 4:20 PM | Talazoparib: From Virtual Drug Discovery to FDA Approval Leonard Post, PhD, CSO, Vivace Therapeutics |
| 4:20 PM – Conference Adjourned | |
| 5:00 PM – 7:00 PM – Post-conference Reception Sponsored by Diamond Sponsors (Engage room and courtyard) | |
| 8:40 AM – 4:45 PM – Conference (Convene room) | |
| 8:40 AM – 7:00 PM – Partnering (Synergy 1 room) | |
| 8:00 AM – 7:00 PM – Exhibition hall (Inspire room) | |